Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 166

1.

Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency.

Gutierrez MJ, Sullivan KE, Fuleihan R; USIDNET Consortium, Bingham CO 3rd.

Semin Arthritis Rheum. 2018 Feb 23. pii: S0049-0172(17)30654-6. doi: 10.1016/j.semarthrit.2018.02.013. [Epub ahead of print]

PMID:
29599028
2.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Mar 21. pii: S0049-0172(18)30042-8. doi: 10.1016/j.semarthrit.2018.02.011. [Epub ahead of print]

PMID:
29573850
3.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

4.

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Albayda J, Bingham CO 3rd, Shah AA, Kelly RJ, Cappelli L.

Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. doi: 10.1093/rheumatology/kex470. No abstract available.

PMID:
29342300
5.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO 3rd, Ritchlin CT, Schwarz EM.

Nat Rev Rheumatol. 2018 Feb;14(2):94-106. doi: 10.1038/nrrheum.2017.205. Epub 2018 Jan 11. Review.

PMID:
29323343
6.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

7.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

PMID:
29070531
8.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

9.

Towards improving measurement of stiffness in rheumatology.

Orbai AM, Bingham CO 3rd.

Rheumatology (Oxford). 2018 Feb 1;57(2):206-208. doi: 10.1093/rheumatology/kex247. No abstract available.

PMID:
28968882
10.

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO 3rd.

J Rheumatol. 2017 Dec;44(12):1884-1888. doi: 10.3899/jrheum.161389. Epub 2017 Aug 15.

PMID:
28811355
11.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

PMID:
28811351
12.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

PMID:
28765256
13.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2017 Nov;44(11):1683-1687. doi: 10.3899/jrheum.161252. Epub 2017 Aug 1. Erratum in: J Rheumatol. 2017 Dec;44(12 ):1944.

PMID:
28765245
14.

Perspectives of survivors, families and researchers on key outcomes for research in acute respiratory failure.

Dinglas VD, Chessare CM, Davis WE, Parker A, Friedman LA, Colantuoni E, Bingham CO, Turnbull AE, Needham DM.

Thorax. 2018 Jan;73(1):7-12. doi: 10.1136/thoraxjnl-2017-210234. Epub 2017 Jul 29.

PMID:
28756400
15.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.

Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

16.

Erosive Rheumatoid Arthritis After Bilateral Hand Transplantation.

Adler BL, Albayda J, Shores JT, Lee WPA, Brandacher G, Bingham CO 3rd.

Ann Intern Med. 2017 Aug 1;167(3):216-218. doi: 10.7326/L16-0588. Epub 2017 Jun 27. No abstract available.

PMID:
28654973
17.

Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition.

Dein E, Sharfman W, Kim J, Gellad F, Shah AA, Bingham CO 3rd, Cappelli LC.

J Immunother. 2017 Oct;40(8):312-314. doi: 10.1097/CJI.0000000000000174.

PMID:
28614096
18.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

19.

Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study.

Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, Turnbull AE.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130. doi: 10.1164/rccm.201702-0372OC.

PMID:
28537429
20.

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis.

Cappelli LC, Palmer JL, Kremer J, Bingham CO 3rd.

Semin Arthritis Rheum. 2017 Oct;47(2):165-169. doi: 10.1016/j.semarthrit.2017.03.024. Epub 2017 Apr 1.

PMID:
28477897

Supplemental Content

Loading ...
Support Center